Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glow-in-the-Dark dyes reveal if IBD drugs hit their target

NCT ID NCT07258641

Not yet recruiting Knowledge-focused Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether fluorescent dyes attached to two IBD drugs (adalimumab and risankizumab) can show where the drugs go in the gut. 30 adults with ulcerative colitis or Crohn's disease will receive a low dose of the labelled drugs, then undergo a special camera procedure 2-3 days later. The goal is to see if this imaging can predict who will respond to treatment, potentially avoiding ineffective therapies and their side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
fluorescently labelled adalimumab and risankizumab
What this could lead to
If successful, this could lead to a way to predict which IBD drug will work for a patient before starting treatment, reducing trial-and-error.
What could go wrong
This is an early-phase imaging study with only 30 participants. It tests feasibility, not treatment effectiveness, and the dyes are experimental. The approach may not translate into routine clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE (CD) ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

  • University Medical Center Groningen

    Groningen, Provincie Groningen, 9713GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.